NCT07265570招募中2 期
A Phase IIa, Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of ISM5411 in Adult Patients With Active Ulcerative Colitis
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 80
- 试验地点
- 51
- 主要终点
- The rate of treatment-emergent adverse events (TEAEs) in each group.
研究概览
简要总结
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of ISM5411 in adult patients with active ulcerative colitis.
详细描述
ISM5411 is a gut-restricted small-molecule prolyl hydroxylase (PHD) inhibitor. It can promote the expression of intestinal mucosal protective genes and maintain the integrity and functions of intestinal barrier together with anti-inflammation. It is expected to become a safe and effective therapy to overcome the shortcomings of traditional simple anti-inflammatory drugs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject who fully understand the content, process and possible adverse events of the study and capable of giving written informed consent form (ICF).
- •Female subjects must be nonpregnancy and nonlactating. Subjects (male or female) are willing to take medically approved effective contraceptive measures from the screening period to 3 months after the last administration and have no sperm or egg donation plan during the study period and within 3 months after the last dose.
- •Male or female between 18 and 75 years of age (inclusive), at the time of signing the ICF.
- •Subject has a diagnosis of ulcerative colitis for at least 3 months prior to colonoscopy during the screening period, and meets the criteria defined in the current protocol.
- •If the subjects have concomitant medication defined in the current protocol, they must meet the relevant criteria to be enrolled.
- •If the subjects have discontinued medication defined in the current protocol, they must meet the relevant criteria to be enrolled.
排除标准
- •Subjects have suspected or diagnosed Crohn's disease (CD), undefined colitis, ischemic colitis, fulminant colitis, toxic megacolon, radiation colitis, gastrointestinal perforation (other than appendicitis or penetrating injury), diverticular disease associated with colitis, enterophthisis, abdominal abscess or fistula, etc.
- •Subjects with previously diagnosed but uneradicated or current gastrointestinal dysplasia.
- •Subjects have received surgery for UC or any other type of major intestinal surgery (i.e., surgical procedure requiring general anesthesia) or are likely to require related surgery during the study.
- •Subjects have evidence of a pathogenic intestinal infection, or have a Clostridium Difficile infection or other intestinal infection within 30 days prior to the screening endoscopy or have tested positive for Clostridium Difficile toxins or other intestinal pathogens at the screening period.
- •Subjects have chronic recurring infection and/or active viral infection that, based on the investigator's clinical assessment, make them an unsuitable candidate for the study.
- •Subjects who are unable to take oral medications and/or have an impact on absorption of medication due to severe malnutrition or disease and surgery, etc., or who are currently receiving or plan to receive total parenteral nutrition (TPN) during the study period.
- •Subjects who have received the relevant treatments defined in the protocol.
- •Subjects with recurrent or disseminated (even if single episode) herpes zoster, or cytomegalovirus infection.
- •Subjects who have the risks of tuberculosis defined in the protocol.
- •Subjects have any of the infection defined in the protocol.
- •Subjects who are known to be allergic to the investigational product or any components of it or who have allergic constitution (allergy to multiple drugs or foods).
- •Subjects have unstable or uncontrolled and clinically significant allergic (except for untreated, asymptomatic, seasonal allergies), hematological, endocrine/metabolic, coagulation, immunologic, pulmonary, cardiovascular, hepatic (expect hepatic steatohepatitis), digestion system (expect UC), genitourinary, psychiatric, oncologic or neurological disease or other medical disorder that would make them ineligible for the study.
- •Subjects have concomitant illness that in the opinion of the investigator, are likely to require systemic glucocorticosteroid therapy during the study (e.g., moderate to severe asthma).
- •Subjects have received major organ surgery (except needle biopsy, tracheotomy, gastrotomy, etc.) or significant trauma within 28 days prior to randomization or is likely to require related surgery during the study.
- •Subjects have history of any malignancy within 5 years of screening, except for successfully treated nonmelanoma skin cancer (NMSC), skin basal cell carcinoma, or localized carcinoma in situ of the cervix.
- •Any abnormal results defined in the protocol were identified during the screening period.
- •Subjects with poorly controlled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg) despite medication at screening.
- •Subjects have a clinically significant abnormal ECG at screening, including QTcF > 450 msec for males and > 470 msec for females.
- •Subjects have difficulty in venous blood collection or history of acupuncture syncope reaction or blood phobia.
- •Subjects have contraindications to colonoscopy, including but not limited to gastrointestinal fistulas, early post abdominal surgery, severe coagulopathy, large abdominal aneurysms, or any condition that the investigator determines significantly increases the risk of colonoscopy complications.
- •Subjects have a history of alcohol or drug abuse within 3 months of screening, according to the judgement of the investigator. Alcohol abuse refers to consuming alcohol at least twice per day or more than 14 units of alcohol per week.
- •Subjects have participated in other clinical trials of other drugs or medical devices within 30 days prior to screening period and have already received the investigational product, or are currently participating in another clinical trial of a drug or medical device.
- •Subjects are deemed by the investigator to be inappropriate for the study; or have any condition which would confound or interfere with the evaluation of the safety, tolerability, or PK of the investigational drug; or are unable or unwilling to comply with the study protocol.
研究组 & 干预措施
Patients assigned to Cohort 1 will receive ISM5411 tablets up to 12 weeks.
Experimental
干预措施: ISM5411 tablets (Drug)
Patients assigned to Cohort 2 will receive ISM5411 tablets up to 12 weeks.
Experimental
干预措施: ISM5411 tablets (Drug)
Patients assigned to Cohort 3 will receive ISM5411 tablets up to 12 weeks.
Experimental
干预措施: ISM5411 tablets (Drug)
Patients assigned to Cohort 4 will receive placebo up to 12 weeks.
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
The rate of treatment-emergent adverse events (TEAEs) in each group.
时间窗: Week1 to Week12.
To evaluate the safety and tolerability of ISM5411.
The rate of serious adverse events (SAEs) and adverse events (AEs) leading to discontinuation of treatment in each group.
时间窗: Up to 16 weeks.
To evaluate the safety and tolerability of ISM5411.
Changes and comparisons of the following data for each group of subjects: vital signs, physical examination, laboratory test(blood routine, blood chemistry, urinalysis, coagulation function, etc.), ECG(Heart rate, RR, PR, QRS,QT, QTcF ), etc.
时间窗: Up to 16 weeks.
To evaluate the safety and tolerability of ISM5411.
次要结局
- Peak plasma concentration (Cmax)(Week1 to Week12.)
- Peak plasma time (Tmax)(Week1 to Week12.)
- Area under the plasma concentration-time curve extrapolated from time zero to infinity (AUC0-inf).(Week1 to Week12.)
- Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-t).(Week1 to Week12.)
- Terminal rate constant (λz)(Week1 to Week12.)
- Elimination half-life (t1/2)(Week1 to Week12.)
- Apparent volume of distribution (Vz/F)(Week1 to Week12.)
- Apparent clearance (CL/F)(Week1 to Week12.)
- Mean residence time (MRT)(Week1 to Week12.)
- Colonic tissue concentration (Ccolon)(Week1 to Week12.)
研究者
研究点 (51)
Loading locations...
相似试验
招募中
2 期
Topical Ketotifen 0.25% for Secondary VestibulodyniaNCT07257029Center for Vulvovaginal Disorders54
招募中
3 期
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor DeficiencyNCT07266805Pharvaris Netherlands B.V.32
招募中
2 期
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLCNCT07264816Sichuan Baili Pharmaceutical Co., Ltd.80
招募中
3 期
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)Cold UrticariaNCT07266402Celldex Therapeutics240
尚未招募
1 期
A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune DiseasesNCT07265206Juventas Cell Therapy Ltd.15